Bio

Bio


As a postdoctoral advisee of Dr. Branimir (Brandy) I. Sikic in Division of Medicine/Oncology at Stanford University School of Medicine I study mechanisms of resistance to anticancer drugs, particularly resistance to clinically valuable taxanes. Most importantly, our goals are to understand mechanisms of taxane resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I, II and III clinical trials, and translational studies of molecular determinants of therapeutic response and toxicity.

Boards, Advisory Committees, Professional Organizations


  • Associate Member, American Association for Cancer Research (AACR) (2013 - Present)
  • Member, American Society for Cell Biology (ASCB) (2013 - Present)

Professional Education


  • Master of Science, St. John's University (2012)
  • Doctor of Philosophy, St. John's University (2015)

Stanford Advisors


Research & Scholarship

Current Research and Scholarly Interests


Multidrug Resistance

Our overall objective is to study the mechanism of multidrug resistance encoded by the ABCB1 gene and its product, P-glycoprotein (P-gp), a transmembrane pump that is responsible for drug efflux and resistance to many natural product chemotherapeutics. Cells enriched with P-gp have altered sensitivities to known anticancer drugs relative to cells that are ABCB1-negative, and ABCB1 is believed to be significant in the clinical response to anticancer therapies involving doxorubicin, paclitaxel and many other compounds.

In an attempt to overcome this form of resistance, we are currently developing modulators of MDR which inhibit the natural function of P-gp and restore sensitivity to drugs in the laboratory.

Our laboratory has identified a mutation in the ABCB1 gene which renders the cell line insensitive to MDR modulation. Studies are on-going to generate other ABCB1 gene mutations in order to determine the mechanism(s) of resistance to MDR modulation associated with alterations in P-gp structure and function. Since these MDR modulators all bind to P-gp, and most are transport substrates, such mutations will be important in defining clinically relevant structure-activity relationships of P-gp.

We are also investigating other mechanisms in cellular models which contribute to drug resistance in the clinic such as the anti-apoptotic proto-oncogene BCL2, and the BIRC family of genes which encode for the inhibitors of apoptosis proteins (e.g. c-IAP1, c-IAP2, XIAP, and Livin).

Taxane Mechanisms of Resistance

The taxanes are widely used as chemotherapy agents and have substantial clinical activity in breast, ovarian, lung, and other cancers. Despite activity in human tumors, development of drug resistance presents a serious clinical problem.

Our objective is to study mechanisms of cellular resistance to taxanes, paclitaxel (Taxol) and docetaxel (Taxotere), and the second generation taxane, cabazitaxel (Jevtana) which was approved for the treatment of hormone-refractory metastatic prostate cancer. Although the major known mechanism of resistance to these agents is multidrug resistance mediated by ABCB1, we hypothesize that the relative expression and composition of tubulin isoforms, the binding targets for these drugs, will differ in resistant cell lines which may alter drug sensitivity.

We have established cellular models of taxane resistance in ovarian and breast cancer cell lines to further study the mechanisms of resistance to this important class of drugs, to explore approaches to overcome drug resistance, and to identify biomarkers for predicting sensitivity or resistance in the clinical setting.

Footer Links:

Stanford Medicine Resources: